Evidence map›Paper›PMID 33074583›Full record

ArticleCancer cytopathology2020

Cytomorphologic features of NTRK-rearranged thyroid carcinoma.

Kartik Viswanathan, Ying-Hsia Chu, William C Faquin, Peter M Sadow

Abstract read
In one paragraph

Article in Cancer cytopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Kartik ViswanathanDepartments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Ying-Hsia ChuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
William C FaquinDepartments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9043-7171
Peter M SadowDepartments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-1036-6367

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4M
NCI NIH HHS P01 CA240239
6 · The paper itself

Abstract

backgroundNTRK-rearranged thyroid carcinomas (NRTC), though rare, harbor a potential therapeutic target. The cytomorphologic features by fine needle aspiration (FNA) and the utility of preoperative molecular testing for NRTC remain largely uncharacterized. We provide a detailed cytomorphologic analysis of an institutional NRTC cohort with clinical, radiologic, histopathologic, and molecular correlations.

methodsOur NRTC FNA cohort included 21 specimens from 19 patients. The mean age and female-to-male ratio were 42 years and 2.2:1, respectively. Predominantly alcohol-stained Papanicolaou smears and liquid-based preparations were reviewed for 14 patients with available materials, and histologic review of subsequent resections was conducted for all 19 patients. Imaging and clinical data were accessed through electronic medical records.

resultsSonographically, NRTC were hypoechoic (87%), predominantly solid (53%) with limited central vascularity (27%), ill-defined borders (67%), and microcalcifications (67%). Observed cytomorphologic features include mixed architectural patterns (79%), fibrosis (93%), oncocytic and vacuolated cytoplasm (36% and 43%, respectively), and abundant intranuclear pseudoinclusions (14%). Most NRTC FNAs were classified as suspicious for malignancy or malignant (89%). One case classified as atypia of uncertain significance underwent ThyroSeq sequencing where a NTRK1 fusion was identified.

conclusionAlthough NRTC did not show a consistent cytomorphologic signature, mixed architectural patterns, prominent fibrosis and distinct cytoplasmic or nuclear features should raise suspicion for NRTC and, when accompanied by negative BRAFV600E by immunohistochemistry on cell block material, aid in selecting cases for molecular testing. This algorithmic approach may help identify potential NRTC, maximizing treatment options for patients, especially in patients for whom treatment planning is complicated.

Indexed as

Gene RearrangementAdolescentAdultAgedBiomarkers, TumorBiopsy, Fine-NeedleCytodiagnosisDiagnosis, DifferentialFemaleFollow-Up StudiesHumansMaleMiddle AgedOncogene Proteins, FusionPrognosisReceptor, trkABiomarkers, TumorNTRK1 protein, humanNTRK3 protein, humanOncogene Proteins, FusionReceptor, trkAReceptor, trkCcytomorphologyFNAhistologykinaseNTRKthyroidthyroid cytology

Identifiers

PMID33074583
PMCPMC8350964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.